Amphastar Pharmaceuticals (AMPH) Liabilities and Shareholders Equity (2013 - 2026)

Amphastar Pharmaceuticals' Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1.35% year-over-year to $1.6 billion in Q1 2026; TTM through Mar 2026 was $6.6 billion, a 5.1% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 3.29% from the prior year.
• Liabilities and Shareholders Equity improved to $1.6 billion in Q1 2026 per AMPH's latest filing, from $1.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q3 2025 and bottomed at $716.2 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $1.5 billion (2023), against an average of $1.3 billion.
• Across the five-year window, Liabilities and Shareholders Equity surged 112.56% in 2023 and climbed 0.04% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $742.0 million in 2022, then jumped by 103.9% to $1.5 billion in 2023, then increased by 4.27% to $1.6 billion in 2024, then advanced by 3.29% to $1.6 billion in 2025, then climbed by 1.16% to $1.6 billion in 2026.
• Per Business Quant, the three latest AMPH Liabilities and Shareholders Equity figures stand at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.7 billion (Q3 2025).